NuCana
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1997-01-01
- Employees
- 28
- Market Cap
- -
- Website
- http://www.nucana.com
- Introduction
NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.
Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
- Conditions
- Advanced CancerAdvanced Solid TumorNeoplasm MalignantMetastatic CancerMelanomaClassical Hodgkin LymphomaNon Small Cell Lung CancerRenal Cell CarcinomaUrothelial CarcinomaHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 19
- Registration Number
- NCT05714553
- Locations
- 🇬🇧
Queen Elizabeth Hospital University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧Guy's and St Thomas NHS Foundation Trust, London, United Kingdom
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
- Conditions
- Colorectal Cancer MetastaticNeoplasm, ColorectalColorectal AdenocarcinomaColorectal CancerColorectal Neoplasms
- Interventions
- Biological: Bevacizumab
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 182
- Registration Number
- NCT05678257
- Locations
- 🇺🇸
Helen F. Graham Cancer Center, Newark, Delaware, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸University of Florida Health Medical Oncology - Davis Cancer Pavilion, Gainesville, Florida, United States
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 773
- Registration Number
- NCT04163900
- Locations
- 🇺🇸
Arizona Oncology Associates , PC - HOPE, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸The Oncology Institute of Hope and Innovation, Whittier, California, United States
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
- Conditions
- Advanced CancerSolid TumorLymphoma
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 135
- Registration Number
- NCT03829254
- Locations
- 🇬🇧
University of Edinburgh, Edinburgh, United Kingdom
🇬🇧The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧The Christie NHS Foundation Trust, Manchester, United Kingdom
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
- Conditions
- Neoplasms, ColorectalColorectal CarcinomaColorectal NeoplasmsColorectal TumorsColorectal Cancer
- Interventions
- Drug: NUFIRIDrug: NUFOX + VEGF pathway inhibitorDrug: NUFOXDrug: NUFIRI + VEGF pathway inhibitorDrug: NUFIRI + EGFR inhibitorDrug: NUC-3373 + bevacizumabDrug: NUFOX + EGFR inhibitor
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 111
- Registration Number
- NCT03428958
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
- Prev
- 1
- 2
- Next